Hattori Aritoshi, Matsunaga Takeshi, Takamochi Kazuya, Oh Shiaki, Suzuki Kenji
Department of General Thoracic Surgery, Juntendo University School of Medicine, 1-3, Hongo 3-chome, Bunkyo-ku, Tokyo, 113-8431, Japan.
Surg Today. 2016 Aug;46(8):914-21. doi: 10.1007/s00595-015-1256-6. Epub 2015 Oct 15.
We investigated the surgical outcomes of clinical-T1b lung adenocarcinomas patients whose tumors had a solid-dominant radiological appearance and who were treated with segmentectomy or lobectomy.
We examined 154 surgically resected clinical-T1b lung adenocarcinomas with a "solid-dominant" appearance on thin-section computed tomography (CT). The preoperative thin-section CT images of all cases were reviewed. "Solid-dominant" was defined as 0.5≤ consolidation/tumor ratio (CTR) <1.0.
Pathological nodal metastasis, lymphatic invasion, vascular invasion, and pleural invasion were found in 7 (4.5 %), 27 (18 %), 21 (14 %), and 15 (10 %) patients with clinical-T1b solid-dominant lung adenocarcinoma, respectively. Lobectomy and segmentectomy were performed in 123 (80 %) and 31 (20 %) cases, respectively. The 3-year overall survival (OS) and relapse-free survival (RFS) of patients with clinical-T1b solid-dominant lung adenocarcinoma were 95.5 and 92.4 %, respectively. The 3-year RFS and OS did not differ significantly between the patients who underwent lobectomy or segmentectomy (3-year RFS, 92.3 vs. 93.4 %, p = 0.8713; 3-year OS, 95.3 vs. 96.6 %, p = 0.7603). Segmentectomy was not found to be a prognostic factor for RFS (p = 0.8714), or OS (p = 0.7613).
Segmentectomy can achieve acceptable oncological outcomes (both in terms of OS and RFS), which are similar to those achieved with standard lobectomy, in patients with clinical-T1b solid-dominant lung adenocarcinoma.
我们研究了临床T1b期肺腺癌患者的手术结果,这些患者的肿瘤在影像学上以实性为主,且接受了肺段切除术或肺叶切除术。
我们检查了154例经手术切除的临床T1b期肺腺癌,这些病例在薄层计算机断层扫描(CT)上表现为“实性为主”。回顾了所有病例的术前薄层CT图像。“实性为主”定义为实变/肿瘤比率(CTR)≥0.5且<1.0。
临床T1b期实性为主型肺腺癌患者中,分别有7例(4.5%)、27例(18%)、21例(14%)和15例(10%)发现有病理淋巴结转移、淋巴管侵犯、血管侵犯和胸膜侵犯。分别有123例(80%)和31例(20%)患者接受了肺叶切除术和肺段切除术。临床T1b期实性为主型肺腺癌患者的3年总生存率(OS)和无复发生存率(RFS)分别为95.5%和92.4%。接受肺叶切除术或肺段切除术的患者的3年RFS和OS差异无统计学意义(3年RFS,92.3%对93.4%,p = 0.8713;3年OS,95.3%对96.6%,p = 0.7603)。未发现肺段切除术是RFS(p = 0.8714)或OS(p = 0.7613)的预后因素。
对于临床T1b期实性为主型肺腺癌患者,肺段切除术可实现与标准肺叶切除术相似的、可接受的肿瘤学结果(在OS和RFS方面)。